Şahin M.T.2024-07-222024-07-22200718715230http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/19229Alefacept is a fully human fusion protein, being the first biologic agent approved for the treatment of chronic, moderate to severe plaque-type psoriasis. Its dual mechanism of action involves inhibition of T-cell activation and selective reduction of memory T cells. It has a slow onset of action, peaking approximately 18 weeks after the first injection. However, it is associated with long remissions without the need for maintenance therapy in psoriatic patients and its efficacy improves with subsequent courses with a high safety profile. The mechanism of action, the results of the clinical trials, its efficacy, pharmacodynamic effects on circulating lymphocytes, and safety and tolerability of alefacept are summarized in this review. Current treatment guidelines are also presented. © 2007 Bentham Science Publishers Ltd.Englishalefaceptcalcipotriolimmunosuppressive agentplacebosteroidalopecia areataautoimmune diseasecapillary leak syndromechillclinical trialcommon colddisease severitydrug costdrug efficacydrug feverdrug induced headachedrug mechanismdrug safetydrug withdrawalhumanimmune deficiencyimmunogenicityinfection riskinjection site reactionlichen planuslow drug dosemaintenance therapymalignant neoplastic diseasememory T lymphocytemonotherapyopportunistic infectionpatient informationpharmacodynamicsphototherapypsoriasisquality of liferemissionreviewside effectsingle drug doseT lymphocyte activationultraviolet B radiationReview10.2174/187152307781368229